GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Gross Profit

WuXi Biologics (Cayman) (FRA:1FW2) Gross Profit : €879 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Gross Profit?

WuXi Biologics (Cayman)'s gross profit for the six months ended in Dec. 2023 was €420 Mil. WuXi Biologics (Cayman)'s gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €879 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. WuXi Biologics (Cayman)'s gross profit for the six months ended in Dec. 2023 was €420 Mil. WuXi Biologics (Cayman)'s Revenue for the six months ended in Dec. 2023 was €1,097 Mil. Therefore, WuXi Biologics (Cayman)'s Gross Margin % for the quarter that ended in Dec. 2023 was 38.25%.

WuXi Biologics (Cayman) had a gross margin of 38.25% for the quarter that ended in Dec. 2023 => Competition eroding margins

During the past 10 years, the highest Gross Margin % of WuXi Biologics (Cayman) was 46.93%. The lowest was 32.44%. And the median was 40.48%.


WuXi Biologics (Cayman) Gross Profit Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Gross Profit Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 212.86 318.40 670.96 910.46 876.89

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 351.83 482.27 448.30 458.91 419.61

Competitive Comparison of WuXi Biologics (Cayman)'s Gross Profit

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Gross Profit distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Gross Profit falls into.



WuXi Biologics (Cayman) Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

WuXi Biologics (Cayman)'s Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2187.671 - 1310.779
=877

WuXi Biologics (Cayman)'s Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=1097.057 - 677.449
=420

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €879 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

WuXi Biologics (Cayman)'s Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=420 / 1097.057
=38.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


WuXi Biologics (Cayman)  (FRA:1FW2) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

WuXi Biologics (Cayman) had a gross margin of 38.25% for the quarter that ended in Dec. 2023 => Competition eroding margins


WuXi Biologics (Cayman) Gross Profit Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines